Clinical Trial Update: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3 [Phase 1]

View source ↗

Summary

A Phase 1 study by Boehringer Ingelheim is testing how well different doses of BI 764532 are tolerated in DLL3-positive glioma patients; the trial is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• BI 764532 (BI 764532)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Glioma | Phase 1 | Status: ACTIVE_NOT_RECRUITING